Biotechnology Cancer Cures Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Biotechnology Cancer Cures

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: WWS who wrote (83)	6/28/1999 9:34:00 AM
From: scaram(o)uche	Read Replies (1) of 226

Bill: p53 insertion is ongoing for at least two groups, Schering-Plough (Canji) and RPR (Introgen). Preliminary results sound OK delivering the gene with adenovirus. Unfortunately, the virus is immunogenic, and I don't expect current efforts to lead to a cure. There is a new approach to deal with the immunogenicity that is being used at PolyMASC, being acquired by Valentis (old MBIO and GMED, merged). Don't hold your breath. Also, there's a thread here at SI for a company that works with an alternative approach for p53 which does not use gene insertion. The mechanism of action is not clear, but pathogenic (replicating) adenovirus seems to have a positive clinical effect. It was originally proposed that the activity was due to selective viral replication in p53 mutant cells. That rationale has fallen to data. The company is Onyx (ONXX), also collaborating with PolyMASC (but I don't know if there's real effort or progress). Dr. Pegram was a honcho in testing anti-Her-2/neu of Genentech. I couldn't find anything from his lab involving p53. Too early? Best of wishes for your friend, Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next